A Phase 1 interventional study of AG2304 and AG23041 and AG23042 in Pharmacokinetics, sponsored by Ahn-Gook Pharmaceuticals Co.,Ltd. Not yet recruiting. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-08.
Sponsored by Ahn-Gook Pharmaceuticals Co.,Ltd · Phase 1, Interventional, and Treatment
The objective of this study is to evaluate the pharmacokinetic characteristics of AG2304 in healthy subjects.
To evaluate the pharmacokinetic characteristics and safety profiles of AG2304 compared with coadministration AG23041 and AG23042 after a single oral dose administration in healthy Korean subjects under fasting conditions.
Ahn-Gook Pharmaceuticals Co.,Ltd is the lead sponsor of 24 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: Coadministration of AG23041 and AG23042, Period 2: AG2304
Drug: AG2304 · Drug: AG23041 and AG23042
Period 1: AG2304, Period 2: Coadministration of AG23041 and AG23042
Drug: AG2304 · Drug: AG23041 and AG23042
AG2304, Single-dose Oral Administration
AG23041/AG23042, Single-dose Oral Administration
AUC
Area under the plasma concentration
Time frame: Pharmacokinetic plasma samples collected over a 72-hour period
Cmax
Peak Plasma Concentration
Time frame: Pharmacokinetic plasma samples collected over a 72-hour period
No study locations are listed for this record.
Start is estimated for Aug 2025; primary completion for Sep 2025, 1 month later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ahn-Gook Pharmaceuticals Co.,Ltd →